Lipocine Inc. — Q2 2022 Form 10-Q
Reporting period: Three and six months ended June 30, 2022. Lipocine is a clinical-stage biopharmaceutical company developing oral drug-delivery products for metabolic, liver, hormone-related and CNS disorders. Its portfolio includes TLANDO and pipeline candidates LPCN 1148, 1144, 1111, 1107, 1154 and 2101.
Financial results and liquidity
| Metric | Q2 2022 | Q2 2021 | Six months 2022 | Six months 2021 |
|---|---|---|---|---|
| Revenue | $500,000 | $0 | $500,000 | $0 |
| Research and development expense | $2.90 million | $1.46 million | $4.79 million | $3.05 million |
| General and administrative expense | $1.13 million | $1.53 million | $2.37 million | $3.06 million |
| Net loss | $2.63 million | $6.81 million | $6.12 million | $10.18 million |
| Basic loss per share | $0.03 | $0.08 | $0.07 | $0.12 |
| Operating cash used | Not stated separately | Not stated separately | $6.93 million | $6.43 million |
The $500,000 revenue was a non-refundable Antares fee for extending its option to license LPCN 1111, not product sales or TLANDO royalties. Lipocine said it expected approximately $235,000 in TLANDO royalties based on estimated Q2 net sales; the payment was expected to reduce the Antares-related contract asset in Q3. The filing reports no product-sale revenue to date. Conventional product margins are therefore not meaningful.
At June 30, Lipocine held $4.98 million in cash and equivalents and $32.41 million in marketable securities, or about $37.4 million in unrestricted cash, equivalents and securities. Total current assets were $38.08 million and current liabilities were $1.71 million. Total assets were $42.19 million; stockholders’ equity was $39.89 million. The company had no debt outstanding after repaying its SVB loan at maturity on June 1, including a $650,000 final payment charge.
For the first half, investing activities provided $11.08 million, mainly from marketable-security maturities; financing activities used $2.12 million, mainly for loan repayments and the final payment charge. Cash, equivalents and restricted cash increased by $2.03 million from year-end 2021, while unrestricted cash, equivalents and marketable securities declined from $46.6 million to $37.4 million.
Material changes and notable items
- Revenue rose from zero, reflecting the Antares option-extension fee. Antares informed Lipocine in June that it would not exercise its option for TLANDO XR/LPCN 1111; Lipocine retains development and commercialization rights.
- TLANDO received FDA approval on March 28, 2022, and Antares announced its commercial launch on June 7. Antares became a Halozyme subsidiary following Halozyme’s May acquisition of Antares.
- R&D expense increased 97% in Q2 and 57% for the first half year over year, principally reflecting LPCN 1148 and LPCN 1154 work. G&A expense fell, mainly due to lower legal costs following the Clarus settlement.
- Net loss improved year over year, largely because 2021 included a $4.0 million Clarus settlement expense. In April 2022, the parties amended the settlement: Lipocine paid $1.25 million in May, eliminating the remaining scheduled payments and reducing the liability by $250,000.
- The warrant liability generated a non-cash gain of $583,445 in Q2 and $205,457 for the first half. Its fair value is sensitive to stock price and other valuation assumptions.
- Accumulated deficit was $178.8 million at June 30. Common shares outstanding were 88,499,124; authorized common shares were increased from 100 million to 200 million in June.
Outlook, development and risks
- Management said existing capital resources were expected to fund projected operating requirements through at least June 30, 2023, including the ongoing LPCN 1148 study, planned LPCN 1154 and LPCN 2101 work, and regulatory compliance. This estimate depends on assumptions; additional studies could use cash sooner. Management expects to need additional capital before or after that date and warns that inability to raise funds could threaten continued operations.
- LPCN 1148 Phase 2 enrollment was expected to finish in the second half of 2022, with 24-week top-line results expected in the first half of 2023. These are forward-looking expectations, not reported results.
- After its July 2022 end-of-Phase-2 meeting, FDA recommended a dose-ranging Phase 2 study for LPCN 1144 before a pivotal study. Lipocine was exploring a partner; no agreement had been made.
- LPCN 1154’s Phase 2 proof-of-concept study was planned for the second half of 2022. FDA accepted the LPCN 2101 IND in July, and the company planned a Phase 2 epilepsy study in the second half of 2022.
- LPCN 1107’s development plan may be affected by FDA review of Makena and its approved generics; an FDA public hearing was scheduled for October 2022. No partnering agreement had been made for LPCN 1107 or LPCN 1111.
- A shareholder securities class action alleging misleading statements about the TLANDO NDA remained unresolved. The company said the outcome was not probable or estimable and recorded no liability; insurance coverage is subject to a $1.25 million retention.
- Nasdaq notified Lipocine in June that its share price had been below the $1 minimum bid for 30 consecutive business days. The company had until December 5, 2022 to regain compliance by meeting the required bid-price test; it said it would consider options, including a reverse stock split.
- Other risks include clinical and regulatory uncertainty, dependence on future financing or licensing, potential dilution, stock-price volatility, and possible Nasdaq delisting. Management reported disclosure controls were effective as of June 30, 2022.
Most important facts for investors to verify
- Whether TLANDO sales translate into royalty receipts, and the timing and amount of any Antares payments.
- Whether cash spending and planned clinical activity remain consistent with management’s stated runway through June 30, 2023, and what financing or partnering options are available.
- Progress and actual results for LPCN 1148, plus the timing, design and funding of FDA-recommended LPCN 1144 dose-ranging work.
- Whether LPCN 1154 and LPCN 2101 studies began as planned, and whether Antares’ decision not to license LPCN 1111 changes its development path or funding needs.
- Resolution of the Nasdaq minimum-bid deficiency and the status and potential exposure of the shareholder class action.